Acumen Pharmaceuticals (Acumen Pharmaceuticals) Cash-to-Debt : 8.55 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Acumen Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Acumen Pharmaceuticals's cash to debt ratio for the quarter that ended in Dec. 2023 was 8.55.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Acumen Pharmaceuticals could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Acumen Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

ABOS' s Cash-to-Debt Range Over the Past 10 Years
Min: 8.55 Med: No Debt Max: No Debt
Current: 8.55

During the past 5 years, Acumen Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 8.55. And the median was No Debt.

ABOS's Cash-to-Debt is ranked better than
53.44% of 1540 companies
in the Biotechnology industry
Industry Median: 6.495 vs ABOS: 8.55

Acumen Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for Acumen Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Acumen Pharmaceuticals Cash-to-Debt Chart

Acumen Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

No Debt

1,691.48

8.55

Acumen Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial												1,691.48	2,095.66	4,995.90	107,717.00	8.55

Competitive Comparison of Acumen Pharmaceuticals's Cash-to-Debt

For the Biotechnology subindustry, Acumen Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acumen Pharmaceuticals's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acumen Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Acumen Pharmaceuticals's Cash-to-Debt falls into.

Acumen Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Acumen Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	243.522	/	(0.866	+	27.621)
	=	8.55

Acumen Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	243.522	/	(0.866	+	27.621)
	=	8.55

Acumen Pharmaceuticals (NAS:ABOS) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Acumen Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Acumen Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Acumen Pharmaceuticals (Acumen Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acumen Pharmaceuticals Inc (NAS:ABOS) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

427 Park Street, Charlottesville, VA, USA, 22902

Website

https://www.acumenpharm.com

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believe to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets amyloid-beta oligomers.

Executives

Daniel Joseph Oconnell	director, officer: President and CEO	C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Derek M Meisner	officer: Chief Legal Office & Corp Sec	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Eric Siemers	officer: Chief Medical Officer	C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Russell Barton	officer: Chief Operating Officer	C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Matt Zuga	officer: Chief Financial Officer	C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Jeffrey L. Ives	director	C/O CARA THERAPEUTICS, INC., 1 PARROTT DRIVE, SHELTON CT 06484
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Derrell Porter	director	C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD. #900, SOUTH SAN FRANCISCO CA 94080
Kimberlee C Drapkin	director	PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Paul B Manning	10 percent owner	200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Stalfort John A Iii	director	C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Robert D. Hardie	10 percent owner	210 RIDGE MCINTIRE ROAD, SUITE 350, CHARLOTTESVILLE VA 22903
Nathan B Fountain	director	C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Sands Capital Global Venture Fund Ii, L.p.	10 percent owner	C/O SANDS CAPITAL VENTURES, LLC, 1000 WILSON BOULEVARD, SUITE 3000, ARLINGTON VA 22209
Sands Capital Life Sciences Pulse Fund, Llc	10 percent owner	C/O SANDS CAPITAL VENTURES, LLC, 1000 WILSON BOULEVARD, SUITE 3000, ARLINGTON VA 22209